|
|
||||||||
J Biol Chem, Vol. 274, Issue 44, 31150-31154, October 29, 1999
From the § Department of Medicine, Institute of
Pathology, Case Western Reserve University, Cleveland, Ohio 44106 and
A variety of environmental stresses
stimulate the mitogen-activated protein kinase/extracellular
signal-regulated kinase (ERK) kinase (MEKK) > stress-activated
protein kinase (SAPK)-ERK kinase (SEK) > SAPK/c-Jun
NH2-terminal kinase (JNK) stress-activated protein
kinase cascade and coordinately activate the transcription factor
NF The MEKK1 protein kinase (2) is a proximate activator of the
stress-activated protein kinase
(SAPK,1 alternatively known
as JNK) stress-signaling pathway (3). A variety of environmental
stresses, including inflammatory cytokines, hyperosmotic shock, and UV
light, stimulate the cascade (4). MEKK1 is implicated in apoptotic cell
death (5, 6), but perhaps surprisingly MEKK1 activates NF Stress activators upstream of MEKK1 remain obscure. The small
G-proteins Rac and Rho activate stress signaling (12, 13), but their
placement in relation to MEKK1 is unclear. TNF Intracellular thiols can be consumed by a process termed "redox
cycling" in which reactive quinones catalyze the oxidation of
sulfhydryls to disulfides. In the cell, reactive quinones are regulated
by the enzymatic activity NAD(P)H dehydrogenase (formerly DT-diaphorase) (E.C. 1.6.99.2) (16), representing a family of cytoplasmic flavo-enzymes responsible for two-electron reduction of
quinones (17), using NADPH or NADH as electron donor. NAD(P)H dehydrogenase, also termed "quinone reductase," is inhibited by dicoumarol, a coumarin derivative (18). Like other coumarins, dicoumarol is used clinically to inhibit blood coagulation processes dependent on vitamin K, a biological quinone.
Here we report evidence that inhibitors of quinone reductases can
inhibit SAPK and NF SAPK Activation Assays--
Human embryonic kidney 293 cells, or
other cells as indicated, were seeded at 105 cells/35-mm
plastic dish and transferred to serum-free medium 18 h before
stimulation as indicated in the figure legends. 20 min following
stimulation with 400 mM sorbitol (or as indicated) cells
were assayed for SAPK/JNK activity as described (3) using rabbit
anti-holo-SAPK- Plasmid Transfections--
Plasmid encoding the catalytic
fragment of MEKK under a CMV promoter have been described (3); these
were transfected into recipient cells using calcium phosphate. The
SAPK- NF To determine whether quinone reductase inhibitors affect
transmission of stress signals, we pretreated cultures of human
embryonic kidney 293 cells with dicoumarol before stimulation with
hyperosmotic sorbitol or anisomycin. Dicoumarol alone did not affect
SAPK but completely blocked activation by osmotic shock and anisomycin in 293 cells (Fig. 1A) and in
Jurkat and resting peripheral T lymphocytes (data not shown and see
below). Dicoumarol also blocked SAPK activation by UV irradiation and
ceramide induced by treatment with sphingomyelinase (Fig.
1B). Warfarin and coumarin, agents that inhibit the vitamin
K cycle like dicoumarol, did not inhibit SAPK activation (see Table
I), suggesting that vitamin K metabolism is unrelated to stress signaling.
Inhibition of SAPK activation by dicoumarol was
dose-dependent (Fig. 2), with
an IC50 between 19 and 38 µM in 293 cells.
Dicoumarol blocked SAPK activation in response to expression of
TRAF2, a TNF
Quinone Reductase Inhibitors Block SAPK/JNK and NF
B
Pathways and Potentiate Apoptosis*
,
,
§¶,
,
Department of Environmental Health, Center for Environmental
Toxicology and Technology, Colorado State University, Fort Collins,
Colorado 80523
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B. Mechanisms of stress activation upstream of MEKK1 have not been
precisely determined. Redox mechanisms involving sulfhydryls are likely
because N-acetyl-cysteine at millimolar concentrations
blocks stress signals. Because intracellular sulfhydryl concentrations
can be regulated through redox cycling involving reactive quinones (1),
we tested the ability of quinone reductase inhibitors to alter stress
signaling. Several quinone reductases are inhibited by dicoumarol, a
coumarin derivative. Dicoumarol prevented SAPK activation in
vivo by chemical cell stressors and also prevented SAPK
activation induced by expression of the tumor necrosis factor
(TNF
) receptor-associated protein TRAF2 but not by expression
of truncated active MEKK1. Other coumarin derivatives failed to block
SAPK activation, but other inhibitors of quinone reductases,
particularly menadione, similarly blocked SAPK activation. Cells
deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells
reconstituted with the NQO1 gene displayed relative dicoumarol resistance. Consistent with the proposed role of overlapping upstream signaling cascades in activation of NF
B, dicoumarol also blocked NF
B activation in primary macrophages stimulated with either lipopolysaccharide or TNF
. In addition, dicoumarol strongly
potentiated TNF
-induced apoptosis in HeLa cells, probably by
blocking the anti-apoptotic effect of NF
B. The ability of dicoumarol
to simultaneously inhibit SAPK and NF
B activation and to potentiate
apoptotic cell death suggests that SAPK is not an obligate participant
in apoptosis. Dicoumarol, currently in clinical use as an oral
anticoagulant, represents a potential therapeutic inhibitor of the SAPK
and NF
B response.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B pathways
(7, 8) that induce expression of genes to counteract the apoptotic
death response (9-11).
and the TNF
receptor-associated effector protein TRAF2 activate the SAPK
pathway (14, 15). Reactive oxygen species are implicated in activation
of stress kinase pathways in response to TNF
and UV irradiation.
Reducing agents such as N-acetyl-cysteine at millimolar concentrations can block stress signals (15), suggesting that redox
mechanisms are required for an undefined and probably early event in
transmission of stress signals.
B signaling. In addition, dicoumarol potentiates
the apoptotic effect of TNF
, probably by preventing anti-apoptotic
events dependent upon NF
B.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1 (p54) antiserum and glutathione
S-transferase-Jun (5-79) as substrate. Anti-MAPK C-terminal
peptide polyclonal serum was obtained from Michael Dunn (Milwaukee,
WI). Following gel electrophoresis, proteins were transferred to
polyvinylidene difluoride membrane and labeled proteins detected and
quantified using a Packard Instant Imager.
1 (p54) allele expressed as a glutathione
S-transferase fusion protein using the pEBG vector was
obtained from James Woodgett (Toronto, Ontario).
B Assays--
Human pulmonary alveolar macrophages were
isolated by bronchoalveolar lavage of healthy adults. Nuclear extracts
were prepared either immediately upon isolation or after 30 min of
incubation in medium with or without LPS or TNF
. DNA binding of
NF
B in nuclear extracts was determined using the radiolabeled
oligonucleotide 5'-CTAGTAGCGGAAAGTCCCTTG-3'. Polyclonal antisera
detecting p65 and p50 amino termini was a gift from Nancy Rice, NCI,
Frederick, MD.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (25K):
[in a new window]
Fig. 1.
Inhibition of SAPK activation by
dicoumarol. 293 cells were preincubated with 300 µM
dicoumarol followed by stimulation with hypertonic sorbitol (400 mM, lanes 3 and 4), anisomycin (10 µg/ml, lanes 5 and 6), sphingomyelinase (from
Bacillus cereus, 10 units/ml, lanes 8 and
9) or UV light (254 nM, 20 J/m2,
lanes 10 and 11) for 20 min. Cells were lysed and
SAPK assayed by in vitro kinase assay. All of these
treatments resulted in strong stimulation of SAPK activity, which was
prevented by the 10 min pre-incubation with 300 µM
dicoumarol.
Inhibition of SAPK by respiratory and redox-active chemicals
receptor interacting protein that activates SAPK
(15) (Fig. 3A). In contrast,
dicoumarol was unable to block SAPK activation in response to
expression of truncated active MEKK1, indicating that the point of
dicoumarol inhibition of SAPK activation lies downstream of
TRAF2 but upstream of MEKK1 in a poorly characterized segment of
the stress-signaling cascade.

View larger version (13K):
[in a new window]
Fig. 2.
Concentration dependence of dicoumarol
inhibition of SAPK. 293 cells were treated with serial dilutions
of dicoumarol, and stimulated with sorbitol as described in Fig. 1. The
IC50 of dicoumarol for SAPK inhibition is approximately
19-33 µM.

View larger version (25K):
[in a new window]
Fig. 3.
A, dicoumarol blocks SAPK activation at
a point upstream of MEKK1 and downstream of TRAF2. 293 cells
were transfected with empty pCMV plasmid (lanes 1 and
2), TRAF2-CMV (lanes 3 and 4)
or
MEKK-EE-CMV plasmid (lanes 5 and 6).
Endogenous SAPK was assayed by immunoprecipitation and in
vitro kinase assay. Dicoumarol reduced basal SAPK activity and
TRAF2-stimulated activity but did not block SAPK activation in
MEKK1 transfected cells. B, dicoumarol does not inhibit
activation of SAPK by heat shock. Cells were stimulated with sorbitol
or anisomycin as above or by incubating at 45 °C for 45 min (heat
shock) The heat shock results represent a longer exposure of the same
gel, because stimulation of SAPK by heat shock is comparatively weaker
than the other stimuli. Dicoumarol failed to inhibit activation of SAPK
by heat shock. C, dicoumarol does not block TPA activation
of MAPK. HeLa cells (used because TPA poorly stimulated MAPK in 293 cells) were treated with 400 mM sorbitol (lanes
3 and 4) or with 1 µg/ml TPA (lanes 5 and
6) for 20 min. Extracts were divided and assayed for SAPK
activation (top) and MAPK activation using immune complex
kinase assays and the indicated substrates. Dicoumarol reduced
activation of both SAPK and MAPK by hypertonic sorbitol treatment
(lane 4) but did not block stimulation of MAPK by TPA
(lane 5).
In contrast to its ability to inhibit activation of SAPK by agents such as sorbitol and anisomycin, dicoumarol failed to inhibit activation of SAPK in response to heat shock (Fig. 3B), which is believed to proceed by an alternate pathway (19). The specificity of dicoumarol inhibition for stress signaling was demonstrated by its failure to inhibit activation of MAPK in CV1 cells in response to TPA (Fig. 3C). However dicoumarol did block MAPK activation resulting from osmotic shock, which likely proceeds via upstream pathways that overlap the SAPK signaling pathway, including the involvement of MEKK1 (20). Thus, dicoumarol inhibition is specific for stress-activated pathways and does not affect mitogenic signaling.
To verify the importance of quinone reductases in stress signaling, we
tested a subline of CHO fibroblasts (clone 77254) deficient in NQO1,
one of the major cellular quinone reductases (21). Although these cells
are still capable of activating SAPK in response to hyperosmotic
sorbitol, they have a reduced IC50 for dicoumarol inhibition of SAPK activation, about 5 µM (Fig.
4A). Reconstitution of NQO1 by
stable expression of the NQO1 gene (21) reduced the sensitivity of
these cells to dicoumarol (Fig. 4B). Thus, inhibition of
SAPK activation by dicoumarol can be partly abrogated by expression of
NQO1, genetically supporting a role for NQO1 and other quinone reductases in stress signaling.
|
We tested whether other metabolic toxins and redox inhibitors might be able to inhibit SAPK activation (Table I). No inhibition of SAPK activation was seen with coumarin or warfarin anticoagulants, inhibitors of mitochondrial oxidative phosphorylation, or extracellular superoxide dismutase or catalase, which reduce intracellular levels of superoxide and hydrogen peroxide, respectively. The vitamin K-related quinone menadione blocked SAPK activation with an IC50 approximately the same as dicoumarol. Notably, menadione is an in vitro substrate of quinone reductases, and competitively inhibits these enzymes in vivo. Two other quinone-related compounds, hydroquinone and butylated hydroxyanisole, inhibited SAPK at lower efficiency, requiring very high concentrations to see a significant inhibition. Thus dicoumarol and menadione, followed by other quinones, were most effective at blocking SAPK activation. These inhibitor studies suggest a role for quinone reduction, rather than events such as oxidative phosphorylation, in stress signaling.
These data suggest that dicoumarol inhibition of SAPK signaling may be
related to a change in the state of quinone reduction in the cell.
Specifically, inhibition of quinone reductases by dicoumarol would
result in a decrease in the levels of reduced quinones in the cell. We
examined whether replacing the reduced quinones would restore the
ability of the cells to signal to SAPK (Fig.
5). Although dicoumarol completely
inhibited activation of SAPK in response to sorbitol (lane
4), the addition of increasing amounts of hydroquinone restored
the SAPK activation in a dose-responsive manner (lanes
5-8). Treating the cells with hydroquinone alone had no effect on
SAPK activity (lanes 9-12). These data suggest that the
inhibition of SAPK activation by dicoumarol is due in large part to the
decrease in reduced quinones that results from the inhibition of
quinone reductases, supporting a role for quinone reduction in
establishing an intracellular environment that is permissive for stress
signaling.
|
We examined consequences of interfering with stress signaling using
dicoumarol. Many stress stimuli, for example TNF
and LPS, activate
both SAPK and the NF
B transcription factor. Recent findings have
suggested that the upstream pathways leading to NF
B activation may
significantly overlap with those for SAPK activation, including a role
for MEKK1 in both signaling cascades (7, 8). Dicoumarol blocked NF
B
activation, indicated by the loss of NF
B-DNA binding activity
induced by LPS or TNF
in human pulmonary alveolar macrophages (Fig.
6A).
|
|
NF
B activation inhibits TNF
induced apoptosis (9-11). Disruption
of TNF
-induced gene expression by cycloheximide or actinomycin D
synergizes with TNF
-induced apoptosis. Like cycloheximide, dicoumarol also potentiated apoptosis of HeLa cells treated with TNF
(Fig. 6B). This synergism is likely a result of the
inhibition of NF
B activation by dicoumarol and points to possible
therapeutic uses for dicoumarol in synergism with this or other
apoptosis-inducing agents. Importantly, the simultaneous inhibition of
SAPK/JNK activation and potentiation of apoptosis demonstrates that
SAPK/JNK activation is not a required event in the apoptotic response.
Peripheral blood lymphocytes undergo DNA synthesis in response to the mitogen PHA. Pretreatment of human peripheral blood lymphocytes with hypertonic NaCl stimulated SAPK and blocked DNA synthesis in response to PHA (Table II). Pretreatment of peripheral blood lymphocytes with dicoumarol before hypertonic shock prevented SAPK activation and restored PHA-stimulated DNA synthesis. Thus, inhibition of PHA-induced cell cycle entry in response to hypertonic shock is a specific stress-induced effect rather than a nonspecific toxic effect. In future experiments, dicoumarol should similarly be useful for identifying other biologic consequences of stress signaling.
|
| |
DISCUSSION |
|---|
|
|
|---|
Our data demonstrate an obligate role for a dicoumarol-inhibitable
activity in stress signaling at a point upstream of MEKK1, and
downstream of osmotic shock, LPS, anisomycin, TNF
, and the TNF
receptor-associated protein TRAF2 (Fig. 7). In contrast, this
dicoumarol sensitive activity appears dispensable for activation of
SAPK by heat shock, which is thought to proceed via a distinct pathway.
Our data supports the hypothesis that heat shock acts via an alternate
pathway which does not share the apparent dependence on quinone
reductase function.
Quinone reductases likely provide an intracellular environment permissive to stress signaling rather than themselves being activated during the signaling. Inhibition of these quinone reductases by dicoumarol would interfere with this environment, and inhibit the ability of the cells to transmit stress signals. In support of this, replacing reduced quinones that are lost as a result of dicoumarol inhibition of quinone reductases restores the ability of the cells to signal to SAPK. These data suggest a role for quinone reduction in generating this permissive intracellular environment. Interestingly, very high concentrations of hydroquinone inhibit activation of SAPK in response to sorbitol, suggesting that there is a tightly regulated balance, where either too high or low levels of reduced quinones are detrimental to stress signal transmission.
Cells lacking NQO1 display increased sensitivity to dicoumarol treatment. The observation that these cells continue to signal to SAPK supports our model in which NQO1 is involved in establishing an intracellular environment permissive for stress signaling, rather than fulfilling an obligate role in a linear pathway. In the absence of NQO1, other less abundant dicoumarol-sensitive quinone reductases assume responsibility for establishing the homeostatic quinone balance. When these NQO1 deficient cells are treated with dicoumarol, this balance is more easily upset, as reflected in the decreased IC50 for SAPK signaling when compared with the cells that have been reconstituted by stable transfection of NQO1.
Inhibition of stress signaling by dicoumarol synergizes with TNF-
to
promote apoptosis, suggesting a role for quinone reductases in the
regulation of apoptotic events. Other evidence similarly supports this
theory. First, using the SAGE technique, it was shown that expression
of the apoptotic regulator p53 strongly activated expression of a
quinone reductase among several other redox enzymes (22). In a separate
study, induction of the p53-induced cell cycle inhibitor p21/cip1/waf1
by aziridinylbenzoquinones was also inhibited by dicoumarol (23),
demonstrating a requirement for quinone reductases in this induction.
NF
B is a central participant in pathologic inflammation (24). SAPK
is also activated in pathologic inflammation, and in other pathologies
such as hepatic regeneration and cirrhosis (25), and in reperfusion
following cardiac and cerebral vascular occlusion (26). Dicoumarol or
similar quinone reductase inhibitors might serve clinically to inhibit
stress and inflammatory processes. Dicoumarol has been used as an oral
anticoagulant in patients for many years. Although it is a poison, the
known toxic effects of its administration in animals are related solely
to anticoagulation, which can be reversed by simultaneous
administration of vitamin K. Inhibition of SAPK and NF
B by
dicoumarol or related compounds might thus prove doubly valuable; first
for identifying the function of stress signals in experimental
situations, and also for translation into therapeutic utility in the
clinical setting.
| |
ACKNOWLEDGEMENTS |
|---|
We thank R. Michael Sramkoski for assistance with flow cytometry at the Case Western Reserve University Cancer Center Core Facility, and Minhong Yan, Tim Shannon, and Edwina Lerner for helpful discussions.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants CA-66134 and ES/HL-09249-01 and awards from the American Cancer Society and the Council for Tobacco Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These authors contributed equally to this work.
¶ Supported by National Institutes of Health Grants HL-57940 and M01-RR-00080.
** To whom correspondence should be addressed. Tel.: 216-368-1266; Fax: 216-368-1300; E-mail: djt2@po.cwru.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: SAPK, stress-activated protein kinase; JNK, c-Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; MEKK, MAPK/extracellular signal-regulated kinase kinase; CMV, cytomegalovirus; LPS, lipopolysaccharide; TPA, 12-O-tetradecanoylphorbol-13-acetate; CHO, Chinese hamster ovary; PHA, phytohemagglutinim.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Brunmark, A., and Cadenas, E. (1989) Free Radic. Biol. Med. 7, 435-477[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Lange-Carter, C. A.,
Pleiman, C. M.,
Gardner, A. M.,
Blumer, K. J.,
and Johnson, G. L.
(1993)
Science
260,
315-319 |
| 3. | Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994) Nature 372, 798-800[Medline] [Order article via Infotrieve] |
| 4. |
Kyriakis, J. M.,
and Avruch, J.
(1996)
J. Biol. Chem.
271,
24313-24316 |
| 5. | Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., and Frisch, S. M. (1997) Cell 90, 315-323[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Deak, J. C.,
Cross, J. V.,
Lewis, M.,
Qian, Y.,
Parrott, L. A.,
Distelhorst, C. W.,
and Templeton, D. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5595-5600 |
| 7. |
Meyer, C. F.,
Wang, X.,
Chang, C.,
Templeton, D.,
and Tan, T. H.
(1996)
J. Biol. Chem.
271,
8971-8976 |
| 8. | Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T. (1997) Cell 88, 213-222[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Beg, A. A.,
and Baltimore, D.
(1996)
Science
274,
782-784 |
| 10. |
Wang, C. Y.,
Mayo, M. W.,
and Baldwin, A., Jr.
(1996)
Science
274,
784-787 |
| 11. |
Van Antwerp, D. J.,
Martin, S. J.,
Kafri, T.,
Green, D. R.,
and Verma, I. M.
(1996)
Science
274,
787-789 |
| 12. | Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Coso, O. A.,
Teramoto, H.,
Simonds, W. F.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
3963-3966 |
| 14. | Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Natoli, G.,
Costanzo, A.,
Ianni, A.,
Templeton, D.,
Woodgett, J.,
Balsano, C.,
and Levrero, M.
(1997)
Science
275,
200-203 |
| 16. | Lind, C., Cadenas, E., Hochstein, P., and Ernster, L. (1990) Methods Enzymol. 186, 287-301[Medline] [Order article via Infotrieve] |
| 17. | Jaiswal, A. K., Burnett, P., Adesnik, M., and McBride, O. W. (1990) Biochemistry 29, 1899-1906[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Hosoda, S.,
Nakamura, W.,
and Hayashi, K.
(1974)
J. Biol. Chem.
249,
6416-6423 |
| 19. |
Adler, V.,
Schaffer, A.,
Kim, J.,
Dolan, L.,
and Ronai, Z.
(1995)
J. Biol. Chem.
270,
26071-26077 |
| 20. |
Yujiri, T.,
Sather, S.,
Fanger, G. R.,
and Johnson, G. L.
(1998)
Science
282,
1911-1914 |
| 21. | Gustafson, D. L., Beall, H. D., Bolton, E. M., Ross, D., and Waldren, C. A. (1996) Mol. Pharmacol. 50, 728-735[Abstract] |
| 22. | Polyak, K., Xia, Y., Zweir, J., Kinzler, K., and Vogelstein, B. (1997) Nature 389, 300-305[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Qui, M. S., and Green, S. H. (1992) Neuron 9, 705-717[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Barnes, P. J.,
and Karin, M.
(1997)
N. Engl. J. Med.
336,
1066-1071 |
| 25. | Westwick, J. K., Weitzel, C., Leffert, H. L., and Brenner, D. A. (1995) J. Clin. Invest. 95, 803-810 |
| 26. |
Bogoyevitch, M. A.,
Gillespie-Brown, J.,
Ketterman, A. J.,
Fuller, S. J.,
Ben-Levy, R.,
Ashworth, A.,
Marshall, C. J.,
and Sugden, P. H.
(1996)
Circ. Res.
79,
162-173 |
This article has been cited by other articles:
![]() |
Y. Jing, J. A. Dowdy, M. R. Van Scott, and J. S. Fedan Hyperosmolarity-Induced Dilation and Epithelial Bioelectric Responses of Guinea Pig Trachea in Vitro: Role of Kinase Signaling J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 186 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hernandez, G. Lopez-Lluch, J. A. Bernal, P. Navas, and J. A. Pintor-Toro Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90 Mol. Cancer Ther., March 1, 2008; 7(3): 474 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-O. Lee, Y.-C. Chang, K. Whang, C.-H. Kim, and I.-S. Lee Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-{alpha}-induced migration of human vascular smooth muscle cells Cardiovasc Res, November 1, 2007; 76(2): 331 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Du, D. H. Daniels, C. Asbury, S. Venkataraman, J. Liu, D. R. Spitz, L. W. Oberley, and J. J. Cullen Mitochondrial Production of Reactive Oxygen Species Mediate Dicumarol-induced Cytotoxicity in Cancer Cells J. Biol. Chem., December 8, 2006; 281(49): 37416 - 37426. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chu and T. J. Ferro Identification of a hydrogen peroxide-induced PP1-JNK1-Sp1 signaling pathway for gene regulation Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L983 - L992. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Ahn, G. Sethi, A. K. Jain, A. K. Jaiswal, and B. B. Aggarwal Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-{kappa}B, I{kappa}B{alpha} Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis J. Biol. Chem., July 21, 2006; 281(29): 19798 - 19808. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Dehn, D. Siegel, K. S. Zafar, P. Reigan, E. Swann, C. J. Moody, and D. Ross 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol. Cancer Ther., July 1, 2006; 5(7): 1702 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1084 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Davison, K. K. Mann, S. Waxman, and W. H. Miller Jr JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells Blood, May 1, 2004; 103(9): 3496 - 3502. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Frost, G. J. Nystrom, and C. H. Lang Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1153 - R1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Dhandapani, M. Hadman, L. De Sevilla, M. F. Wade, V. B. Mahesh, and D. W. Brann Astrocyte Protection of Neurons: ROLE OF TRANSFORMING GROWTH FACTOR-{beta} SIGNALING VIA A c-Jun-AP-1 PROTECTIVE PATHWAY J. Biol. Chem., October 31, 2003; 278(44): 43329 - 43339. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Dehn, D. Siegel, E. Swann, C. J. Moody, and D. Ross Biochemical, Cytotoxic, and Genotoxic Effects of ES936, a Mechanism-Based Inhibitor of NAD(P)H:quinone Oxidoreductase 1, in Cellular Systems Mol. Pharmacol., September 1, 2003; 64(3): 714 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Kater, M. P. Peppelenbosch, D. P. M. Brandjes, and M. Lumbantobing Dichotomal Effect of the Coumadin Derivative Warfarin on Inflammatory Signal Transduction Clin. Vaccine Immunol., November 1, 2002; 9(6): 1396 - 1397. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-E. Janelle, A. Gravel, J. Gosselin, M. J. Tremblay, and L. Flamand Activation of Monocyte Cyclooxygenase-2 Gene Expression by Human Herpesvirus 6. ROLE FOR CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN AND ACTIVATOR PROTEIN-1 J. Biol. Chem., August 16, 2002; 277(34): 30665 - 30674. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pipaon, P. Gutierrez, J. C. Montero, M. Lorenzo, A. Eguiraun, J. A. De la Fuente, A. Pandiella, J. Leon, and J. M. Ortiz Mitogen-activated Protein Kinase Routes as Targets in the Action of Diaza-anthracene Compounds with a Potent Growth-inhibitory Effect on Cancer Cells Mol. Cancer Ther., August 1, 2002; 1(10): 811 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ryten, P. M. Dunn, J. T. Neary, and G. Burnstock ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells J. Cell Biol., July 22, 2002; 158(2): 345 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Mc Gee, G. Campiani, A. Ramunno, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer Activation of the c-Jun N-terminal Kinase (JNK) Signaling Pathway Is Essential during PBOX-6-induced Apoptosis in Chronic Myelogenous Leukemia (CML) Cells J. Biol. Chem., May 17, 2002; 277(21): 18383 - 18389. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. LaRochelle, V. Gagne, J. Charron, J.-W. Soh, and C. Seguin Phosphorylation Is Involved in the Activation of Metal-regulatory Transcription Factor 1 in Response to Metal Ions J. Biol. Chem., November 2, 2001; 276(45): 41879 - 41888. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsuguchi, T. Musikacharoen, T. R. Johnson, A. S. Kraft, and Y. Yoshikai A Novel Mitogen-Activated Protein Kinase Phosphatase Is an Important Negative Regulator of Lipopolysaccharide-Mediated c-Jun N-Terminal Kinase Activation in Mouse Macrophage Cell Lines Mol. Cell. Biol., October 15, 2001; 21(20): 6999 - 7009. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chakravortty, Y. Kato, T. Sugiyama, N. Koide, M. M. Mu, T. Yoshida, and T. Yokochi Inhibition of Caspase 3 Abrogates Lipopolysaccharide-Induced Nitric Oxide Production by Preventing Activation of NF-{kappa}B and c-Jun NH2-Terminal Kinase/Stress-Activated Protein Kinase in RAW 264.7 Murine Macrophage Cells Infect. Immun., March 1, 2001; 69(3): 1315 - 1321. [Abstract] [Full Text] [PDF] |
||||
< |